



POWERING AFFORDABLE CARE

with insights that cut through complexity

Quest's expansive autoimmune testing and services pave the way.





Simplifying the path to diagnosis and optimized care

Autoimmune and rheumatic disorders are particularly difficult to diagnose because they can present with a variety of nonspecific, overlapping symptoms. Plus, these symptoms often vary from patient to patient.

Because no single test delivers a definitive diagnosis for any one autoimmune disease, diagnosing a patient can often require comprehensive, cutting-edge testing.

Autoimmune diseases by the numbers¹

Scientists are continuing to learn more about autoimmune diseases on a daily basis.

100+

Autoimmune diseases are a group of more than 100 chronic conditions

24MM

In the US, autoimmune diseases affect more than 24 million people, while 8 million more have auto-antibodies

5%-10%

Autoimmune diseases cluster: 5%-10% of Americans have more than one autoimmune disease

80%

Approximately 80% of all patients diagnosed with autoimmune diseases are women

Get answers earlier to power better outcomes

Early diagnosis for autoimmune disease and identification of autoimmune disorders means you can start your patient's therapy sooner. This can lead to remission with no active inflammation or functional deterioration.²

Count on our expansive menu of autoimmune testing to provide reliable insights that enable timely action, regardless of the complexity of the case.



- **150+** specialized assays and panels for autoimmune diseases
- Tests for screening, diagnosis, and monitoring of **80+** autoimmune diseases


Constant innovations that advance testing

Our goal is to provide reliable insights that power fast action across the patient continuum of care. That's why we continually increase the breadth of our testing and complement it with cutting-edge technology like immunofluorescence assays (IFA).

Backed by more than 50 years of experience, we leverage our vast automation and lab expertise to drive faster test turnaround times and more effective testing approaches.

Improve diagnosis for autoimmune conditions with cutting-edge tests

Our portfolio can clarify symptoms related to a broad range of autoimmune diseases and help provide differential diagnosis even for the most challenging cases that involve rare diseases.



Leading in autoimmune diagnostics

We constantly evaluate new biomarkers to develop innovative panels and assays, as well as educational resources for the medical community.

In fact, we were the first lab to offer 14-3-3 η testing. Our deep investment in R&D enabled us to launch 6 new autoimmunity tests in 2020 during the COVID-19 pandemic.



A portfolio that supports the entire patient journey

Featured solutions from our broad menu of 150+ autoimmune tests



Diagnosis: Understand the cause of your patient's symptoms

ANALyzer™ ANA IFA with Reflex Titer/Pattern Systemic Autoimmune Panel 1

Leverages gold standard IFA to screen for ANA with reflex to titers and tests for 25 analytes from a single sample, minimizing follow-up testing and expediting diagnosis

Rheumatoid Arthritis Diagnostic IdentRA® Panel 2

Combines 14-3-3 η with rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody to improve diagnostic sensitivity in the early diagnosis of rheumatoid arthritis (RA)



Treatment selection: Know when your patient is ready for biologic therapy

Prebiologic Panel

Includes guideline-recommended tests to evaluate patients for biologic or biosimilar therapy:

- Hepatitis B screening
- Hepatitis C screening
- Tuberculosis infection screening (interferon gamma release assay or IGRA)



Treatment monitoring and management: Personalize patient care for improved outcomes

14-3-3 η protein

14-3-3 η can be tested serially to monitor response to disease-modifying antirheumatic drugs (DMARD) and anti-tumor necrosis factor (TNF) drugs.^{3,4}

Adalimumab and infliximab Testing

- Measures TNF blocker drug levels and/or antidrug antibodies
- Informs the best treatment strategy (e.g., adjust dose or switch drugs)

Seamless access to testing and insights

Powering insights with expertise in specialty care


- **Network of 600+ MDs, PhDs, and genetic counselors** you can consult with on test selection and results interpretation, even after hours
- **Scientific publications each year** that share key insights on autoimmune diagnostics with the scientific and medical community
- **Broad test menu** covering all specialties and intersecting clinical areas such as gastroenterology, neurology, and more


Powering efficiency with intuitive experiences

- **Connectivity with 600+ EHRs** enables faster report delivery and keeps lab results and relevant clinical information at your fingertips
- **Quantum® software** allows you to easily manage all laboratory-related tasks on a single platform; includes built-in graphics to visualize utilization and trends over time

Powering convenient, affordable testing for your patients

- **Broad, in-network access:** We're in network for 92% of lives nationwide and have preferred lab network status with major health plans, enabling us to deliver pricing at time of service for patients and prevent surprise bills
- **2,250+ Patient Service Centers:** Patients can get tested when and where it is most convenient for them, ensuring swift access to testing
- **Online appointment scheduling:** Appointments can be easily scheduled, viewed, or changed online by patients
- **MyQuest™ patient portal:** Our portal allows patients to check results, share results with multiple providers, and schedule medication reminders anytime, anywhere, and on any device





Learn more at QuestAutoimmuneTesting.com
Reach out to a Quest representative at 1.866.MYQUEST

References

1. Autoimmune Association. About Autoimmunity. Accessed December 6, 2021. <https://autoimmune.org/resource-center/about-autoimmunity/>
2. Konforte D, Diamandis EP, van Venooij WJ, et al. Autoimmune diseases: early diagnosis and new treatment strategies. *Clin Chemistry*. 2012;58(11):1510-1514. doi: 10.1373/clinchem.2012.189480
3. Britsemmer K, Maksymowich WP, van Schaardenburg D, et al. FRI0059 14-3-3 eta is an early RA biomarker that is modifiable with standard DMARDS and corresponds with improvement in clinical variables. *Ann Rheum Dis*. 2013;72(suppl 3):A388. doi: 10.1136/annrheumdis-2013-eular.1186
4. Maksymowich WP, van Schaardenburg D, van der Heijde D, et al. 91% of early RA patients are positive for serum 14-3-3 η or its autoantibodies. *Arthritis Rheum*. 2013;Poster presentation.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved. SB10996 12/2022

